Supplementary Figure S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1

Supplementary figure S2 shows the deletion of AEBP1 in human CAF subclusters. (A) UMAP showing the subtypes identified in the dataset. (B) Expression (in scTransform values) of AEBP1 across subtypes in non-transfected and AEBP1-perturbed cells. (C) Plasmid map of pRDA_208 that was used to generate AEBP1 KO human CAFs.